A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial

BACKGROUND: The current standard treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma (DLBCL) primarily consists of intensified salvage therapy and, if the disease is chemo-sensitive, high dose therapy followed with autologous stem cell transplantation. In the rituxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Witzens-Harig, Mathias, Memmer, Marie Luise, Dreyling, Martin, Hess, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701613/
https://www.ncbi.nlm.nih.gov/pubmed/23799873
http://dx.doi.org/10.1186/1471-2407-13-308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701613/
https://www.ncbi.nlm.nih.gov/pubmed/23799873
http://dx.doi.org/10.1186/1471-2407-13-308

Ejemplares similares